These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32507128)

  • 1. Evaluation of the effect of naltrexone coadministration on the pharmacokinetics of oxycodone in a randomized phase 1 clinical trial
.
    Kleideiter E; Buller S; Nemeth R; Terlinden R; Rengelshausen J
    Int J Clin Pharmacol Ther; 2020 Aug; 58(8):439-448. PubMed ID: 32507128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
    Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
    Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
    Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.
    Gosai P; Ducharme MP; Godfrey AR; Freeman JC; Monif T; Kumar KS; Kumar S; Mudnaik R; Katikaneni P
    Int J Clin Pharmacol Ther; 2013 Nov; 51(11):895-907. PubMed ID: 23673291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.
    Smith K; Hopp M; Mundin G; Leyendecker P; Bailey P; Grothe B; Uhl R; Reimer K
    Clin Ther; 2008 Nov; 30(11):2051-68. PubMed ID: 19108793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ethanol on the pharmacokinetics of extended-release oxycodone with sequestered naltrexone (ALO-02).
    Malhotra BK; Matschke K; Wang Q; Bramson C; Salageanu J
    Clin Drug Investig; 2015 Apr; 35(4):267-74. PubMed ID: 25724154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability of oxycodone after administration of a new prolonged-release once-daily tablet formulation in healthy subjects, in comparison to an established twice-daily tablet
.
    Scheidel B; Maritz MA; Gschwind YJ; Steigerwald K; Guth V; Kovacs P; Rey H
    Int J Clin Pharmacol Ther; 2017 Nov; 55(11):881-890. PubMed ID: 28933336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal abuse potential of an abuse-deterrent oxycodone formulation compared to oxycodone immediate release and placebo in nondependent, recreational opioid users.
    Setnik B; Schoedel K; Bartlett C; Dick C; Hakim N; Geoffroy P
    J Opioid Manag; 2017; 13(6):449-464. PubMed ID: 29308591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions.
    Devarakonda K; Morton T; Margulis R; Giuliani M; Barrett T
    Drug Des Devel Ther; 2014; 8():1125-34. PubMed ID: 25170252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study.
    Webster LR; Kinzler ER; Pantaleon C; Iverson M; Aigner S
    Adv Ther; 2019 Jul; 36(7):1730-1740. PubMed ID: 31065992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and Bioequivalence Evaluation of a New Oxycodone Tamper-Resistant Tablet Administered with an Opioid Antagonist in Patients with Chronic Pain.
    Luo Z; Miao J; Shu S; Wang Y; Zhu X; Hu C; Shen Y
    Clin Drug Investig; 2020 Feb; 40(2):139-148. PubMed ID: 31679120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relative bioavailability of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA®) and an extended release morphine sulfate capsule formulation (KADIAN®) in healthy adults under fasting conditions.
    Johnson FK; Ciric S; Boudriau S; Kisicki JC; Stauffer J
    Am J Ther; 2011 Jan; 18(1):2-8. PubMed ID: 20864883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.
    Darwish M; Yang R; Tracewell W; Robertson P; Bond M
    Clin Ther; 2015 Feb; 37(2):390-401. PubMed ID: 25542074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users.
    Setnik B; Bass A; Bramson C; Levy-Cooperman N; Malhotra B; Matschke K; Geoffroy P; Sommerville KW; Wolfram G
    Pain Med; 2017 Jun; 18(6):1077-1088. PubMed ID: 27550954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pooled post hoc analysis of population pharmacokinetics of oxycodone and acetaminophen following a single oral dose of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets.
    Franke RM; Morton T; Devarakonda K
    Drug Des Devel Ther; 2015; 9():4587-97. PubMed ID: 26316698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence and absence of food.
    Sathyan G; Xu E; Thipphawong J; Gupta SK
    BMC Clin Pharmacol; 2007 Feb; 7():2. PubMed ID: 17270055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pharmacokinetics and bioavailability of tapentadol following oral administration of immediate- and prolonged-release formulations.
    Göhler K; Brett M; Smit JW; Rengelshausen J; Terlinden R
    Int J Clin Pharmacol Ther; 2013 Apr; 51(4):338-48. PubMed ID: 23357834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single-dose, 3-way crossover pharmacokinetic comparison between immediate-release oxycodone hydrochloride with aversion technology (IRO-A, Oxecta), IRO-a with Niacin, and Oxycodone Hydrochloride (Roxicodone) in healthy adults under fasting conditions.
    Leibowitz MT; Zamora CA; Brzeczko AW; Stark JG
    Am J Ther; 2014; 21(2):99-105. PubMed ID: 22357166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the oral human abuse potential of Oxycodone DETERx® formulation (Xtampza® ER).
    Meske D; Kopecky EA; Passik S; Shram MJ
    J Opioid Manag; 2018; 14(5):359-372. PubMed ID: 30387859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.